Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure

• Published in: Arquivos brasileiros de cardiologia Vol. 106; no. 2; pp. 145 - 152
• Main Authors: Villacorta, Humberto, Maisel, Alan S
• Format: Journal Article
• Language: English; Portuguese
• Published: Brazil Sociedade Brasileira de Cardiologia - SBC 01.02.2016; Sociedade Brasileira de Cardiologia (SBC)
• Subjects: Biomarcadores Farmacológicos; Biomarkers - blood; CARDIAC & CARDIOVASCULAR SYSTEMS; Disease Management; Heart Failure - blood; Heart Failure - physiopathology; Heart Failure - therapy; Humans; Insuficiência Cardíaca; Interleukin-1 Receptor-Like 1 Protein; Prognosis; Prognóstico; Receptores de Interleucina; Receptors, Cell Surface - blood; Reference Values; Review; Risk Assessment - methods; Solubility; terapia; Time Factors; Prognosis; Receptores de Interleucina; Prognóstico; Heart Failure / therapy; Biomarkers, Pharmacological; Insuficiência Cardíaca; terapia; Receptors, Interleukin; Biomarcadores Farmacológicos
• ISSN: 0066-782X; 1678-4170; 1678-4170
• DOI: 10.5935/abc.20150151

ST2 is a member of the interleukin-1 receptor family biomarker and circulating soluble ST2 concentrations are believed to reflect cardiovascular stress and fibrosis. Recent studies have demonstrated soluble ST2 to be a strong predictor of cardiovascular outcomes in both chronic and acute heart failure. It is a new biomarker that meets all required criteria for a useful biomarker. Of note, it adds information to natriuretic peptides (NPs) and some studies have shown it is even superior in terms of risk stratification. Since the introduction of NPs, this has been the most promising biomarker in the field of heart failure and might be particularly useful as therapy guide.